In Tours, France, Franck Michoux creates customized active ingredients for cosmetics by subjecting plants to brutal levels of stress. Time is of the essence: The first product must be launched on the market in November. ... MORE
Following mechanical completion of the facility, Evonik has announced the official start-up of its new multi-layer coextrusion plant for PMMA flat films. ... MORE
Evonik Industries AG has signed an agreement with One Equity Partners to acquire US-based PeroxyChem for US$625 million. ... MORE
On 31 October 2018 Evonik Industries completed the acquisition of Porphyrio NV, the KU Leuven spin-off company head-quartered in Herent ... MORE
Evonik increased adjusted EBITDA to €692 million in the third quarter of 2018. ... MORE
• Company continues to focus on high-margin specialty chemicals businesses • US site transferred to Permira funds on November 1 • Proceeds in the high double-digit million range (USD) ... MORE
Evonik has become the first company in the world to develop a polymer filament based on PEEK (polyether ether ketone) in implant-grade quality for use as a 3D printing material ... MORE
High-performance materials such as VESTOSINT® from Evonik are increasingly making 3D printing, which is also known as additive manufacturing, suitable for series production. ... MORE
Evonik supports the “Arggonauts” of the Fraunhofer Institute of Optronics, System Technologies, and Image Exploitation. The team is participating in the XPRIZE Ocean Discovery competition. ... MORE
Evonik is a world leader in development and manufacturing of innovative materials for additive manufacturing. A new website showcases how we enable 3D printing for things to come. ... MORE
Evonik Industries AG has signed an agreement with One Equity Partners to acquire US-based PeroxyChem for US$625 million. ... MORE
Liposomes transport active pharmaceutical ingredients to the target cells, while ensuring that the cargo does not break down prematurely during its journey through the body. Their use opens up new therapeutic pathways for the treatment of cancer as well as genetic and other diseases. ... MORE
Evonik increased adjusted EBITDA to €692 million in the third quarter of 2018 (prior-year: €640 million). The two growth segments – Nutrition & Care and Resource Efficiency – contributed considerable earnings growth, helping to increase profitability. ... MORE
